BIOCRYST PHARMACEUTICALS INC 8-K

What Happened

• On May 6, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) announced recent corporate developments and reported its financial results for the quarter ended March 31, 2026. The company issued a press release and referenced a conference call and webcast to discuss the business update and quarterly results. The press release is furnished as Exhibit 99.1 to the Form 8‑K.

Key Details

• Filing date: May 6, 2026; quarter covered: ended March 31, 2026.
• Press release title: “BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update” (Exhibit 99.1).
• Company referenced a conference call and webcast to discuss the results and corporate developments.
• The press release was furnished under Item 2.02 (Results of Operations and Financial Condition) and incorporated under Regulation FD (Item 7.01).

Why It Matters

• This 8‑K is the company’s official disclosure that it has completed and publicly released its Q1 2026 earnings and a business update — material information investors use to assess recent performance and near‑term outlook.
• The accompanying webcast and press release are the primary sources for the actual financial figures and management commentary; investors should review Exhibit 99.1 and listen to the call for revenue, profit/loss, cash position and operational highlights, and watch for the subsequent quarterly SEC filings (e.g., Form 10‑Q) for full financial statements and details.